Intelligent Medicine Original, leveraging its proprietary AI drug design platform TranProteins, has successfully developed a GLP-1 receptor agonist (GLP-1 RA) with an extended half-life and enhanced efficacy. The next-generation GLP-1 RA boasts a half-life (T1/2) three times longer than semaglutide, marking a significant milestone in achieving long-acting weight loss medications. This is also the world’s first AI-designed blockbuster weight loss drug.
Using proprietary algorithms, Intelligent Medicine Original designed over tens of thousands of novel GLP-1 RA protein peptide sequences. Through its independently developed high-efficiency screening process, three candidate peptide drugs were successfully identified, followed by animal efficacy and pharmacokinetics studies.
The AI-powered high-throughput drug design and screening capabilities of TranProteins have significantly shortened the drug design cycle and greatly improved the success rate of drug development. These experimental results, achieved within a single experimental cycle, further validate Intelligent Medicine Original’s technological leadership in protein drug design. Its proprietary protein design methods can also be broadly applied to the development of other protein-based drugs, providing strong support for innovative drug research and development.